After months of uncertainty and grim headlines, some scientists are hesitantly recognizing what could be good news. During the first weeks of the Covid-19 pandemic, it was estimated that around 60% of the population would need to be exposed to the coronavirus to achieve herd immunity, which occurs when a high percentage of the community is immune to a disease.
A large-scale antibody study in Spain found that around 5% of the population had contracted the coronavirus, with significant differences between the regions in the Soria province, the figure was more than 14%, compared to 1.2% in Cdiz. The hope of achieving herd immunity seemed like a long shot. But as time passed, a growing amount of research began to suggest that more people are protected against the coronavirus, or at least its most serious versions, than the antibody studies indicated. Experts, however, do not want this news to be used as an excuse for the relaxation of coronavirus safety measures.
When there is an infection from a virus of the same family there could be a cross-reaction and the immune system could develop antibodies similar to the ones that neutralized the other virus
We have been living with coronaviruses for a very long time. Most of them cause minor respiratory problems [like the common cold], while others are more serious, like SARS and MERS, explains Juan Pablo Horcajada, the head of infectious diseases at the Mar Hospital in Barcelona. Four viruses in the coronavirus family cause around 25% of colds, and it is well known that when there is an infection from a virus of the same family there could be a cross-reaction and the immune system could develop antibodies similar to the ones that neutralized the other virus, he explains. What we dont know yet is if these antibodies can offer protection and if so, to what extent.
A study recently published in the journal Science estimated that at least 20% or perhaps up to 50% of people who have never contracted SARS-CoV-2 have some kind of cellular protection against the disease. It is likely this has been generated by previous contact with one of the coronaviruses that cause colds. The research, however, has been done on cell samples and the hypothesis still needs to be tested out in real situations and on real people. For now, the authors of the study, researchers from La Jolla Institute for Immunology in the United States, acknowledge that it is very speculative to link the better prognosis of some Covid-19 patients with their previous exposure to the coronaviruses that cause the common cold.
Similar research from other groups has found the presence of protective T cells, the white blood cells that destroy infected cells in the body, in between 40% and 81% of samples. This would explain the behavior of the pandemic in the last few weeks, says Manel Juan, the head of immunology at Clnic hospital in Barcelona. Although there is concern about the rise in cases, we are not seeing a repeat of the situation in March [when there were hundreds of daily deaths and hospitalizations] and this could be because a greater percentage of people are protected than is reflected in the antibody tests.
According to one study, up to 50% of people who have never contracted SARS-CoV-2 have some kind of cellular protection against the disease
Luisa Villar, the head of immunology at the Ramn y Cajal hospital in Madrid, says that more infections would have been expected, given that only 11% of people in the Madrid region have had the coronavirus, according to the serological study.
According to Villar, the response of T cells, developed by contact with similar viruses or a persons very immune system, could also explain the heterogeneous impact of the disease. In young people, T cells are more active, but this response starts to decline from the age of 70, she says. Thats why young people may have a minor case or even be asymptomatic, while seniors have much more serious symptoms.
One of the reasons why coronaviruses can cause colds is that they share a viral spicule protein that is used to colonize host cells. The laboratories working on a vaccine for Covid-19 see this spicule as the key to developing an immunological response.
While the research may explain why young people have less serious cases of Covid-19, it does not explain the gap in the contagion rates between Spains 17 regions. I would have thought that there would have been more protection in the north of Spain, because you would think there would be more colds there, but thats not what we are seeing, says Juan.
In young people, T cells are more active, but this response starts to decline from the age of 70
Jess Rodrguez Bao, the head of infectious disease at the Virgen Macarena hospital in Seville, also backs the hypothesis that people have more immunity to Covid-19 because they have been in contact with similar diseases, but says there still needs to be epidemiological confirmation of the data. Its a similar situation with the flu. There is a certain degree of immunity after contracting a virus like the flu, he explains, adding that given the virus has led to a global pandemic its unlikely that the immunity is widespread.
A better understanding of the immunity of a population could shed light on the mysteries that remain about why Covid-19 affects people so differently. But measuring real immunity, beyond the presence of antibodies, requires tests that are expensive and difficult to carry out. In Barcelona, Manel Juan is leading a European project to develop an easier and faster test for determining who has immunity from T cells. This information could be used to help find out who is protected and to what extent, and also help design new vaccines, which help the body to generate a more efficient reaction against the coronavirus. For the moment, however, the good news that people who have never had contact with the virus can be protected needs confirmation via research.
English version by Melissa Kitson.
- Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off - R&D World - April 27th, 2025 [April 27th, 2025]
- Dr. Sabine Ehrt Named Chair of the Department of Microbiology and Immunology at Weill Cornell Medicine - WCM Newsroom - April 19th, 2025 [April 19th, 2025]
- RayThera launches with $110 million to advance immunology pipeline - The Pharma Letter - April 10th, 2025 [April 10th, 2025]
- Celebrate Vaccines: The legacy of the tetanus vaccine - British Society for Immunology - April 10th, 2025 [April 10th, 2025]
- Another immunology biotech emerges as Hillstar takes flight with $67M - Endpoints News - March 30th, 2025 [March 30th, 2025]
- Alumnus discovers passion for immunology, teaching at Mercer - Mercer University - March 15th, 2025 [March 15th, 2025]
- The future of immunology - Johnson & Johnson - March 5th, 2025 [March 5th, 2025]
- Immunotherapys Sweet Future: Wrapping up AACR IO 2025 With Glyco-immunology - American Association for Cancer Research (AACR) - March 5th, 2025 [March 5th, 2025]
- J&J receives three CHMP recommendations for immunology and oncology indications - PMLiVE - March 5th, 2025 [March 5th, 2025]
- Greater Austin Allergy, Asthma & Immunology now open in the Shops at the Galleria - Community Impact - March 5th, 2025 [March 5th, 2025]
- As dengue spreads, researchers discover a clue to fighting the virus - La Jolla Institute for Immunology - February 25th, 2025 [February 25th, 2025]
- Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business... - February 25th, 2025 [February 25th, 2025]
- PhD candidate Jesse Lehman receives Kirschstein Award to study immunology - UMass Medical School - February 25th, 2025 [February 25th, 2025]
- Cross-priming in cancer immunology and immunotherapy - Nature.com - February 3rd, 2025 [February 3rd, 2025]
- Sanofi Happy To Spend To Hit Immunology Top Spot - News & Insights - February 3rd, 2025 [February 3rd, 2025]
- The Converging Therapeutic Landscape of Oncology and Immunology: Accelerating Innovation in Biotech - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- Immunology - The Scientist - January 23rd, 2025 [January 23rd, 2025]
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]